Policy Developments - The National Health Commission will enhance investment guarantees for childcare services, aiming for significant improvements in service quality by the end of 2027, including better management systems and increased registration rates for childcare institutions [2] Drug and Device Approvals - Bristol-Myers Squibb's Opdivo has been approved by the European Commission for use in a perioperative treatment regimen for high-risk resectable non-small cell lung cancer (NSCLC) patients, marking it as the first PD-(L)1 inhibitor approved for this indication in the EU [4] Capital Markets - Jiuzhoutong announced a participation in establishing a 25 million yuan industry fund, with a significant contribution of 22.99 million yuan, indicating a strategic move to foster innovation in pharmaceuticals and digital healthcare [5] - AbbVie has entered a collaboration with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapies across multiple disease areas, with an upfront payment of $335 million and potential milestone payments totaling billions [6][7] Corporate Changes - Bluefan Medical announced a change in its indirect controlling shareholder, with Langhui Petrochemical acquiring a 52.0395% stake in Bluefan Investment, although the actual controller remains unchanged [8] - ST Muyu will remove risk warnings and change its name to Tianmu Pharmaceutical starting May 20, 2025, with an increase in daily price fluctuation limits from 5% to 10% [9] Industry Events - WuXi AppTec's investee company Hanbang Technology was listed on the Shanghai Stock Exchange on May 16, 2025, with WuXi holding 6.04% of the total shares post-IPO [10] Market Sentiment - Jinhe Biology's controlling shareholder plans to reduce its stake by up to 3% of the total shares, primarily to repay pledged debts [11] - ABA-Bio has completed a reduction of its stake in Yifang Bio by 9.23 million shares, representing 1.60% of the total shares [12]

益方生物科技（上海）股份有限公司 股东减持股份结果公告 证券代码：688382 证券简称：益方生物 公告编号：2025-021 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 公司于近日收到股东 ABA-Bio 出具的《关于减持股份结果的告知函》，现 将相关减持结果公告如下： | 股东名称 | ABA-Bio | | | | --- | --- | --- | --- | | | 控股股东、实控人及一致行动人 | □是 | √否 | | 股东身份 | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | 一、减持主体减持前基本情况 1 大股东持有的基本情况：本次减持计划实施前，益方生物科技（上海）股份 有限公司（以下简称"公司"）股东 ABA-Bio（Hong Kong）Limited（以下 简称"ABA-Bio"）持有公司股份 32,940,037 股，占公司总股本的 5.70%。 股东持有的股份为 IPO 前取得。 减持计划的实施结果情况： ...

A股创新药概念集体回调，迈威生物跌超10%，百济神州、信立泰双双跌超8%，益方生物、舒泰神、热 景生物、百利天恒、诺诚健华等跌幅靠前。 ...

早盘 创新药概念集体回调， 迈威生物跌超10%， 百济神州、 信立泰双双跌超8%， 益方生物、 舒泰 神、 热景生物、 百利天恒、 诺诚健华等跌幅靠前。 ...

Core Viewpoint - The article discusses the disparity in employee compensation within the A-share pharmaceutical and biotechnology sector for the year 2024, highlighting the highest and lowest average salaries among companies in the industry. Group 1: Highest Average Salaries - The top ten companies with the highest average employee salaries in the pharmaceutical and biotechnology sector are predominantly innovative drug companies, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - The average salary of BeiGene's R&D personnel is 956,000 yuan, with domestic R&D personnel earning an average of 592,000 yuan and overseas R&D personnel earning 1,586,000 yuan [2] - Other companies in the top ten include Dizal Pharmaceutical (迪哲医药) with an average salary of 686,700 yuan and Yihong Pharmaceutical (亚虹医药) with an average salary of 627,400 yuan [2][3] Group 2: Lowest Average Salaries - The ten companies with the lowest average salaries in the sector have an average salary as low as 70,500 yuan, with the lowest being 70,500 yuan at Yisheng Pharmaceutical (益盛药业) [7][9] - The majority of these low-salary companies are traditional Chinese medicine firms and offline pharmacy businesses, with four being Chinese medicine companies [10] - Companies like Teva Pharmaceutical (特一药业) reported a significant decline in net profit, leading to a 10.1% decrease in average salary compared to 2023 [11] Group 3: Salary Trends and Industry Insights - Among the 498 companies in the pharmaceutical and biotechnology sector, 49 companies have an average salary above 300,000 yuan, while 144 companies fall between 200,000 to 300,000 yuan [8] - The article notes that the average salary for most innovative drug companies has increased compared to 2023, with the highest increase being 13.62% for Ailisi (艾力斯) [6] - The article also highlights the challenges faced by offline pharmacies, with a significant drop in customer traffic and profitability due to changes in healthcare policies and increased competition [11][12]

Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [8][29]. Core Insights - The industry is experiencing a return to normal growth, with a notable performance in chemical pharmaceuticals, while the overall revenue growth for 2024 is projected to decline by 0.6% year-on-year, marking the first decline in recent years [12][14]. - The report highlights a significant disparity among sectors, with chemical pharmaceuticals showing a remarkable net profit growth of 97.7%, while biological products face substantial short-term performance pressure [17][18]. - The current low allocation and valuation levels present a high cost-performance ratio for investments in the pharmaceutical sector, suggesting it is an excellent time to allocate resources [19][28]. Summary by Sections 1. Innovation in the Pharmaceutical Chain - The report notes that the impact of national procurement and anti-corruption measures is gradually diminishing, leading to a normal release of rigid demand in hospitals [11]. - The overall revenue growth for the industry in 2024 is projected at -0.6%, with net profit and non-recurring net profit declining by 8.1% and 5.9% respectively [12][13]. 2. Investment Recommendations - The report suggests focusing on the innovation drug supply chain (Biotech + CXO + upstream) and certain overseas medical devices, recommending companies such as Aosaikang, Yifang Bio, and WuXi AppTec for investment [29]. - For in-hospital products (traditional Chinese medicine, chemical pharmaceuticals, and medical devices), companies like Hengrui Medicine and Mindray Medical are highlighted as having more certain growth prospects [29]. 3. Market Positioning - The report indicates that the allocation of public fund products in pharmaceutical stocks has decreased from 11.2% in Q1 2024 to 8.7% in Q4 2024, with a slight recovery to 9.1% by Q1 2025 [19][21]. - The pharmaceutical sector's price-to-earnings ratio is at a 10-year low, suggesting potential for growth as innovative products continue to emerge [22][24].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by more than 15% over the next 6-12 months [5][12]. Core Insights - The company achieved a revenue of 169 million yuan in 2024, a decrease of 9.02% year-on-year, with a net loss attributable to the parent company of 240 million yuan [1][3]. - The successful approval of Gsorese tablets in November 2024 marks a significant milestone, alongside positive results from the D-2570 Phase II clinical trial for psoriasis [2][3]. - The company is advancing its clinical research with multiple products in various stages, including D-0502 in Phase III trials and D-0120 in Phase II trials [2]. Financial Summary - Revenue projections show a recovery with expected growth rates of 36.80% in 2025 and 35.89% in 2026, reaching 231 million yuan and 314 million yuan respectively [4][8]. - The net profit forecast for 2025 and 2026 has been revised down to -257 million yuan and -223 million yuan, respectively, with a new estimate for 2027 at -46 million yuan [3][4]. - The company’s total assets are projected to decline from 2,162 million yuan in 2023 to 1,438 million yuan by 2027, while total liabilities are expected to increase slightly [9]. Clinical Development Progress - The D-2570 product is being developed for multiple indications, including psoriasis, ulcerative colitis, and Crohn's disease, with promising clinical results indicating significant efficacy compared to existing treatments [2][3]. - The company has two products already authorized for sale and several others in various stages of clinical trials, showcasing a robust pipeline [2]. Market Performance - The current stock price is 22.56 yuan, with a market capitalization of approximately 13.047 billion yuan [5]. - The stock has shown a relative performance increase of 129.75% over the past year, indicating strong market interest [7].

从所属行业来看，养老金持有股票主要集中在医药生物、国防军工、电子行业，分别有4只、4只、4只 个股上榜。 从持有时间来看，养老金账户连续持股超过两个报告期的有15只，煜邦电力、凯立新材等均被养老金连 续持有11个报告期。 业绩方面，养老金持有个股中，一季报净利润同比增长的有10只，净利润增幅最高的是华丰科技，公司 一季报共实现净利润3181.10万元，同比增幅为207.17%，净利润同比增幅居前的还有煜邦电力、天德钰 等，净利润分别增长168.08%、116.96%。 市场表现方面，养老金持有的科创板股中，4月以来平均下跌2.50%。从具体个股看，益方生物累计涨 幅18.18%，表现最好，华丰科技、世华科技等分别上涨18.08%、13.43%位居其后。跌幅最大的是传音 控股，累计下跌17.35%。（数据宝） 科创板股机构持股动向曝光，一季度末养老金共现身20只科创板股前十大流通股东榜，新进5只，增持5 只。 养老金持有的科创板股 证券时报·数据宝统计显示，养老金最新出现在20只科创板股前十大流通股东名单中，合计持股量 6788.10万股，期末持股市值合计31.68亿元。持股变动显示，新进5只，增持5只，减持2 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688382 证券简称：益方生物 公告编号：2025-020 益方生物科技（上海）股份有限公司 关于股东权益变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 ■ （二）本次权益变动情况 重要内容提示： ● 本次权益变动属于益方生物科技（上海）股份有限公司（以下简称"公司"）持股5%以上股东履行此 前已披露的减持股份计划以及股权激励归属导致的被动稀释，不触及要约收购。 ● 本次权益变动后，公司股东ABA-Bio（Hong Kong）Limited（以下简称"ABA-Bio"）合计持有公司股 份28,916,393股，持股比例变动至5.00%。 ● 本次权益变动不会导致公司控股股东、实际控制人发生变化。 近日，公司收到股东ABA-Bio的书面通知，现将本次权益变动情况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人基本信息 2025年4月29日，ABA-Bio通过集中竞价方式合计转让公司股份4,023,644股，持股比例由5.73% ...